Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia
{{output}}
Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced l... ...
